Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019
3-Year Update for the Phase 3 Voretigene Neparvovecrzyl Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease
Stephen R. Russell, MD
Updates from the Field
2018
Ziv-aflibercept Efficacy in Better Regulating Neovascular AMD (ZEBRA) Trial
Kapil G. Kapoor, MD
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more